[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624253":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":21,"centralContacts":27,"locations":33,"responsibleParty":54,"collaborators":21,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":21,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":21,"enrollmentInfo":65,"targetDuration":21,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":35,"whyStopped":21,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Institute of Oncology Ljubljana","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Combination Chemotherapy Followed by Ablative SBRT","EXPERIMENTAL","Participants receive standard first-line systemic chemotherapy. Patients without disease progression after initial chemotherapy undergo ablative stereotactic body radiotherapy (SBRT) to the primary pancreatic tumor, followed by continuation of systemic therapy according to institutional practice.",[13,14],"Radiation: Ablative Stereotactic Body Radiotherapy (SBRT)","Drug: Standard First-Line Chemotherapy",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"RADIATION","Ablative Stereotactic Body Radiotherapy (SBRT)","Ablative stereotactic body radiotherapy (SBRT) delivered to the primary pancreatic tumor after initial chemotherapy in patients without disease progression.",[9],null,{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":21},"DRUG","Standard First-Line Chemotherapy","Standard first-line systemic chemotherapy administered according to institutional guidelines (e.g., modified FOLFIRINOX or gemcitabine plus nab-paclitaxel), followed by continuation of systemic therapy after SBRT as clinically indicated.",[9],[28],{"name":29,"role":30,"phone":31,"phoneExt":21,"email":32},"Janja Ocvirk, MD","CONTACT","01 5879 220","jocvirk@onko-i.si",[34],{"facility":5,"status":35,"city":36,"state":21,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"RECRUITING","Ljubljana","1000","Slovenia","SI",{"type":41,"coordinates":42},"Point",[43,44],14.50513,46.05108,{"lat":44,"lon":43},[47,51],{"name":48,"role":30,"phone":49,"phoneExt":21,"email":50},"Klavdija Korošec","+386 31630065","kkorosec@onko-i.si",{"name":52,"role":30,"phone":21,"phoneExt":21,"email":53},"Neža Gros","ngros@onko-i.si",{"type":55,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100624253","combined-chemotherapy-and-ablative-radiotherapy-sbrt-as-first-line-treatment-in-locally-advanced-inoperable-pancreatic-cancer-sbrt-panc-100624253",false,"NCT07407231","Combined Chemotherapy And Ablative Radiotherapy (SBRT) As First-Line Treatment In Locally Advanced Inoperable Pancreatic Cancer (SBRT-PANC)","Efficacy Of Combination Chemotherapy And Ablative Radiotherapy (SBRT) In The First-Line Treatment Of Locally Advanced Inoperable Pancreatic Cancer","Inclusion Criteria:\n\n* Adults aged 18 years and older\n* Locally advanced, inoperable pancreatic cancer\n* Treated with first-line systemic chemotherapy followed by stereotactic body radiotherapy (SBRT) at participating centers\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Metastatic pancreatic cancer\n* Prior systemic therapy for locally advanced pancreatic cancer (one or more previous lines of systemic treatment)\n* Disease progression after initial chemotherapy prior to SBRT\n* Any condition that, in the investigator's opinion, would interfere with study participation or evaluation","ALL","18 Years",{"count":66,"type":67},18,"ESTIMATED","INTERVENTIONAL",[70],"NA","This prospective interventional clinical study evaluates the efficacy and safety of combining systemic chemotherapy followed by ablative stereotactic body radiotherapy (SBRT) as first-line treatment in adult patients with locally advanced, inoperable pancreatic cancer.\n\nThe study aims to determine the response rate after SBRT delivered following initial chemotherapy, as well as time to disease progression and treatment-related toxicity. Patients receive standard first-line chemotherapy and, in the absence of disease progression, undergo ablative SBRT to the primary tumor, followed by continuation of systemic therapy according to clinical practice.\n\nThe study is conducted in Slovenia, with patient enrollment expanded to additional participating clinical centers following an approved amendment.",[73],"Locally Advanced Pancreatic Cancer",[75,76],"SBRT","Stereotactic Body Radiotherapy","2026-02-12",{"date":79,"type":80},"2026-02-17","ACTUAL",{"date":82,"type":80},"2021-09-01",{"date":84,"type":67},"2026-12-31",{"name":5,"class":6},1]